Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial

Proton beam radiotherapy (PBT) has recently been applied to treat hepatocellular carcinoma (HCC); however, there is no randomized controlled trial-based evidence on its safety and efficacy. We compared the outcomes of PBT and radiofrequency ablation (RFA) in patients with recurrent/residual HCC (rHC...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2021-03, Vol.74 (3), p.603-612
Hauptverfasser:	Kim, Tae Hyun, Koh, Young Hwan, Kim, Bo Hyun, Kim, Min Ju, Lee, Ju Hee, Park, Boram, Park, Joong-Won
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdominal Pain - etiology Ablation Adverse events Aged Alanine Alanine transaminase Alanine Transaminase - blood Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - radiotherapy Clinical trials Female Gastroenterology & Hepatology Hepatocellular carcinoma Humans Leukocyte Count Life Sciences & Biomedicine Liver cancer Liver Neoplasms - blood Liver Neoplasms - epidemiology Liver Neoplasms - radiotherapy local progression-free survival Male Middle Aged Neoplasm Recurrence, Local - radiotherapy Patients Pneumonitis Population Progression-Free Survival Proton Therapy - adverse effects Radiation Pneumonitis - etiology Radiation therapy Radiofrequency ablation Radiofrequency Ablation - adverse effects Radiofrequency ablation: proton beam therapy Randomised controlled trial Republic of Korea - epidemiology Science & Technology Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Proton beam radiotherapy (PBT) has recently been applied to treat hepatocellular carcinoma (HCC); however, there is no randomized controlled trial-based evidence on its safety and efficacy. We compared the outcomes of PBT and radiofrequency ablation (RFA) in patients with recurrent/residual HCC (rHCC) in a phase III non-inferiority trial. Patients with rHCC (size
ISSN:	0168-8278 1600-0641
DOI:	10.1016/j.jhep.2020.09.026